EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.

Dong, Rui-Fang; Zhu, Miao-Lin; Liu, Ming-Ming; Xu, Yi-Ting; Yuan, Liu-Liu; Bian, Jing; Xia, Yuan-Zheng; Kong, Ling-Yi

Dong, Rui-Fang; Zhu, Miao-Lin; Liu, Ming-Ming; Xu, Yi-Ting; Yuan, Liu-Liu; Bian, Jing; Xia, Yuan-Zheng; Kong, Ling-Yi.

Afiliação

Dong RF; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Zhu ML; Department of Pathology, Jiangsu Cancer Hospital, 210009 Nanjing, China.
Liu MM; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Xu YT; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Yuan LL; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Bian J; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China.
Xia YZ; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China; Key laboratory of High-Incidence-Tumour Prevention & Treatment (Guangxi M
Kong LY; Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 24 Tong Jia Xiang, 210009 Nanjing, China. Electronic address: cpu_lykong@126.com.

Pharmacol Res ; 167: 105583, 2021 05.

Article em En | MEDLINE | ID: mdl-33775864

Assuntos

Carcinoma Pulmonar de Células não Pequenas/genética; Resistencia a Medicamentos Antineoplásicos; Neoplasias Pulmonares/genética; Mutação; Inibidores de Proteínas Quinases/farmacologia; Animais; Antineoplásicos/farmacologia; Antineoplásicos/uso terapêutico; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Receptores ErbB/antagonistas & inibidores; Receptores ErbB/genética; Humanos; Neoplasias Pulmonares/tratamento farmacológico; Mutação/efeitos dos fármacos; Inibidores de Proteínas Quinases/uso terapêutico

Palavras-chave

Alflutinib (PubChem CID: 118861389); Almonertinib (PubChem CID: 121280087); EAI045 (PubChem CID: 121231412); EGFR mutations; EGFR-TKI resistance; Future development; JBJ-04-125-02 (PubChem CID: 124173751); JND3229 (PubChem CID: 137628688); NSCLC; Osimertinib (PubChem CID: 71496458); Overcoming drug resistance; Poziotinib (PubChem CID: 25127713); TAK-788 (PubChem CID: 118607832); TAS6417 (PubChem CID: 117918742); TQB3804 (PubChem CID: 138911391)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Neoplasias Pulmonares / Mutação Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google